In response to Morris et al.'s "Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine"

Journal of Medical Toxicology

Volumn 5, Issue 4, 2009, Pages 259-

  Gillman, Ken ^a  

^a NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CHLORPROMAZINE; DOPAMINE RECEPTOR BLOCKING AGENT; OLANZAPINE; SEROTONIN 2A ANTAGONIST; BENZODIAZEPINE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; SEROTONIN AGONIST;

ACUTE TOXICITY; ADVERSE OUTCOME; BODY TEMPERATURE MEASUREMENT; CONSERVATIVE TREATMENT; DIAGNOSTIC ERROR; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; EARLY INTERVENTION; ENZYME ACTIVATION; HEAT LOSS; HEAT STROKE; HEAT TRANSFER; HUMAN; HYPERPYREXIA; HYPOTHERMIA; LETTER; MALIGNANT HYPERTHERMIA; MENTAL DETERIORATION; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; PARKINSONISM HYPERPYREXIA SYNDROME; THERMAL CONDUCTIVITY; INTOXICATION; NOTE; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BROMOCRIPTINE; CHLORPROMAZINE; DISEASE PROGRESSION; DOPAMINE AGONISTS; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; OVERDOSE; SEROTONIN AGONISTS; TREATMENT OUTCOME;

EID: 75349108073     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/BF03178278     Document Type: Letter

References (8)

1. Morris E, Green D, Graudins A. Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine. J Med Toxicol. 2009;5(1):24-26.
2. Lee JW. Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome. Ann Clin Psychiatry. 2007;19(1):9-16.
3. Thomas A, Onofrj M. Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, Parkinsonism-hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal. Mov Disord. 2005;20(12):1671.
4. Cussac D, Boutet-Robinet E, Ailhaud MC, et al. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008;594(1-3): 32-38.
5. Chang CP, Chen SH, Lin MT. Ipsapirone and ketanserin protects against circulatory shock, intracranial hypertension, and cerebral ischemia during heatstroke. Shock. 2005;24(4): 336-340.
6. Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther. 2002;303(2):815-822.
7. Cox B, Kerwin R, Lee TF. Dopamine receptors in the central thermoregulatory pathways of the rat. J Physiol. 1978;282: 471-483.
8. Onofrj M, Thomas A. Acute akinesia in Parkinson disease. Neurology. 2005;64(7):1162-1169.